Because compensatory mechanisms exist in cells for loss of CDK2/cyclin E activity48, inhibition of CDK12 and/or CDK13 may be a more effective approach to treat deadly cancers such as high-grade serous ovarian carcinoma. This evidence concerns the gene CDK13 and ovarian serous carcinoma.